Today, Merck announced that it’s submitting an FDA application for a new antiviral that can be used against COVID19: molnupiravir. If approved, high risk people would take four capsules twice a day for five days early in their infection. This pill series cuts the risk of hospitalization or death in half. Two other antiviral pills (by Pfizer and Atea Pharmaceuticals and Roche) are expected within the next few months.
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to log in.